Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

IPO

Thumbnail
February 26, 2021

A Spac makes it happen for 4D Pharma

The boom in blank-cheque companies could offer small UK developers a new route to a US stock market listing.

Thumbnail
February 18, 2021

The reckoning begins for biotech-focused Spacs

The clock is ticking for the flood of blank-cheque companies that raised money last year, and competition is only getting hotter.

Article image
Vantage logo
February 11, 2021

Biotech flotations offer venture funds an accelerating exit

Start-ups floated faster than usual in 2020, a new analysis finds. For a deeper look at biopharma deal trends, our free report is available to download today.

Article image
Vantage logo
January 29, 2021

Ortho Clinical takes a haircut

Discount pricing and poor first day defies the recent trend for floating device makers.

Article image
Vantage logo
January 18, 2021

Astounding success greets newly public device makers

2020 was a bountiful year for medtechs making their public debut, with one group, Inari Medical, more than quadrupling in value.

Article image
Vantage logo
January 13, 2021

After a big year, biotech flotations have much to do

Whether investor enthusiasm for drug stocks holds up this year is the burning question for IPO followers.

Article image
Vantage logo
December 10, 2020

What the coming year might hold for biopharma

Big events for 2021 include the FDA’s decision on aducanumab and pivotal readouts in diabetes and autoimmunity, while investor enthusiasm will be closely monitored.

Article image
Vantage logo
October 08, 2020

Mapping the transatlantic divide for biotech flotations

A look at how drug developers fare after floating in Europe suggests why many tread a path to the US and a Nasdaq listing.

Article image
Vantage logo
October 06, 2020

Hints of moderation emerge in biotech venture funding

Venture cash raised by private drug developers dipped slightly after two record-breaking quarters, but the party is far from over.

Article image
Vantage logo
October 05, 2020

Few clues to flotation fever in past performance

Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.

Article image
Vantage logo
October 01, 2020

Another huge quarter for biotech flotations

Drug developers raised a record $4.5bn in IPOs in the third quarter, and investor support for biopharma shows little sign of waning.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.